What Does an Adrenal Nodule Mean?
An adrenal nodule is a mass originating from the adrenal gland measuring at least 1 cm that is most commonly a benign, nonfunctioning adenoma (80-85% of cases), but requires systematic evaluation to exclude two critical concerns: malignancy and hormone excess, both of which significantly impact morbidity and mortality. 1
Understanding the Clinical Significance
The incidence of adrenal nodules has increased 10-fold over the past 30 years, primarily due to widespread use of cross-sectional imaging 1. These lesions are now detected in 4-10% of abdominal CT scans and affect approximately 1.4% of the general population, rising to 3.2% in those over 65 years 1.
What Most Adrenal Nodules Are:
- 80-85% are benign adrenocortical adenomas
- Up to 70% are nonfunctioning (produce no hormones)
- Approximately 30% are functioning adenomas that produce hormones 1
The Two Critical Questions That Determine Your Next Steps:
The primary approach to evaluation focuses on excluding malignancy and hormone excess—comprehensive clinical and biochemical assessment alongside imaging is critical for all patients 1.
Risk Stratification by Size
Size is the single most important predictor of malignancy risk:
A critical caveat: Even lesions < 4 cm should be discussed at a multidisciplinary conference if they have concerning imaging features, as 91% of adrenocortical carcinomas were < 4 cm in a large review 1.
Immediate Evaluation Required
Imaging Workup:
All adrenal lesions > 1 cm require dedicated imaging with non-contrast CT (NCCT) as the first-line study 1. The imaging characteristics determine the next steps:
- Homogeneous lesions with NCCT attenuation ≤ 10 HU: Considered benign, no further imaging needed 1
- NCCT attenuation 11-20 HU and < 4 cm: Immediate additional imaging (adrenal protocol CT, MRI with chemical shift, or PET-CT) OR follow-up imaging at 12 months 1
- Heterogeneous lesions ≥ 4 cm OR NCCT attenuation > 20 HU: Relevant malignancy risk—discuss at multidisciplinary conference for consideration of surgical resection 1
Biochemical Testing:
All adrenal nodules ≥ 1 cm require hormonal evaluation 2, as approximately 40% are functional and imaging cannot determine functional status 3. This includes screening for:
- Pheochromocytoma (can cause life-threatening hypertensive crisis)
- Primary aldosteronism
- Cortisol excess
- Androgen production (when clinically indicated)
Special High-Risk Populations
Patients < 40 Years or Pregnant:
These patients have higher risk of malignancy and hormone excess and require urgent MRI assessment (preferred over CT) 1. Surgical resection should be considered for any lesion not characteristically benign on imaging 1.
Patients with History of Malignancy:
While adrenal lesions in cancer patients have higher likelihood of metastasis, less than 30% actually represent metastases 1. However, up to 70% of indeterminate lesions in these patients are malignant 1.
Critical pitfall: Always exclude pheochromocytoma biochemically even when metastasis seems most likely, as pheochromocytomas can cause significant morbidity and imaging cannot reliably differentiate them from metastases 1.
Follow-Up Strategy
For indeterminate lesions chosen for surveillance rather than immediate surgery:
- Initial follow-up: NCCT or MRI at 6-12 months 1
- Stability criteria: Lesions stable for at least 12 months can usually be considered benign without ongoing imaging 1
- Growth thresholds requiring action: Enlargement ≥ 5 mm AND increase in maximum diameter > 20% warrants surgical consideration 1
Important caveat: Even stable lesions require hormone excess exclusion, as some functioning tumors like pheochromocytomas may remain stable in size 1.
Long-Term Risk in Initially Benign Lesions:
Patients with initially benign, nonfunctioning adrenal incidentalomas have:
- 0.2% risk of developing adrenal malignancy
- Up to 2.1% risk of developing clinically relevant hormone excess 1
Bottom Line for Clinical Action
Every adrenal nodule ≥ 1 cm requires both imaging characterization and biochemical evaluation to exclude the two life-threatening conditions: malignancy and hormone-secreting tumors. The specific pathway depends on size, imaging characteristics, patient age, and cancer history, but no adrenal nodule should be dismissed without systematic evaluation 1.